AdJane is a clinical-stage vaccine platform company supporting long-term pandemic preparedness and global health, including applications in antimicrobial resistance.
Our next-generation platform is based on native Outer Membrane Vesicles (nOMVs) derived from Neisseria meningitidis and provides intrinsic innate immune activation. This enables its use as a self-adjuvanting platform for antigen presentation.
The platform has been clinically evaluated in a mucosal respiratory virus vaccine setting, where a favorable safety profile was observed. It supports both intramuscular and mucosal vaccine development, enabling flexibility across different transmission routes and public-health objectives.
Pandemic preparedness is increasingly recognized as a structural, long-term challenge, rather than a sequence of isolated emergency responses. While rapid vaccine development has proven possible in acute situations, sustaining readiness over time requires technologies that can be maintained, adapted and redeployed.
Preparedness therefore depends on platforms that can be preserved, adapted and reused across scenarios, rather than rebuilt for each emerging threat.
Beyond emerging threats, our platform has shown it can be rapidly directed against unknown threats with zoonic and pandemic potential – a capability that directly supports Disease X preparedness.
AdJane’s next-generation platform provides a robust and repeatable foundation for vaccine development across multiple disease contexts, supporting both rapid response and long-term preparedness strategies.
For partnership enquiries: partnering@adjane.com
Or use the below contact form.